Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 6/20 | 0.38 |
| ▸ | GSK3B | P49841 | 6/20 | 0.38 |
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 4/20 | 0.33 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.33 |
| ▸ | SRC | P12931 | 3/20 | 0.33 |
| ▸ | JAK2 | O60674 | 2/20 | 0.33 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | PLK1 | P53350 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16775466 | 0.84 | CYP2C19 (0.33) | GSK3AGSK3BCYP3A4CYP2C9 | |
| SCHEMBL31152368 | 0.84 | CYP2C19 (0.33) | GSK3AGSK3BCYP3A4CYP2C9 | |
| SCHEMBL31152357 | 0.83 | JAK2 (0.43) | FLT3SRCJAK2KDRCYP3A4 | |
| SCHEMBL12573129 | 0.83 | JAK2 (0.43) | FLT3SRCJAK2KDRCYP3A4 | |
| SCHEMBL18270927 | 0.83 | AURKA (0.43) | GSK3AGSK3BFLT3JAK2ROCK2 | |
| SCHEMBL5138075 | 0.77 | RPS6KA5 (0.37) | — | |
| SCHEMBL15393439 | 0.75 | LPL (0.41) | LPLLIPGJAK2CXCR2LIPE | |
| SCHEMBL12572870 | 0.75 | KIT (0.50) | GSK3BCDK2KIT | |
| SCHEMBL21961971 | 0.75 | MAPK1 (0.42) | PIK3CDPIK3CB | |
| SCHEMBL22947113 | 0.74 | GSK3A (0.35) | GSK3AGSK3BLPLLIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11345700-B2 | Methods of preparing inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210008072-A1 | FORMULATIONS OF AZAINDOLE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED | 2021-01-14 | — | — | US | disclosed |
| EP-3294717-B1 | METHODS OF PREPARING INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMA (US) | 2020-07-29 | — | — | EP | disclosed |
| US-20200207765-A1 | METHODS OF PREPARING INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2020-07-02 | — | — | US | disclosed |
| US-10640501-B2 | Methods of preparing inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-05-05 | — | — | US | disclosed |
| EP-3147284-B1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMA (US) | 2019-09-25 | — | — | EP | disclosed |
| US-10023569-B2 | Methods of preparing inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-07-17 | — | — | US | disclosed |
| US-20180134730-A1 | IMPROVED PROCESS FOR PREPARING BORYL 7-AZAINDOLE COMPOUNDS | BOROPHARM INC (US) | 2018-05-17 | — | — | US | disclosed |
| US-20180134730-A1 | IMPROVED PROCESS FOR PREPARING BORYL 7-AZAINDOLE COMPOUNDS | BOROPHARM INC (US) | 2018-05-17 | — | — | US | disclosed |
| US-9908878-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-03-06 | — | — | US | disclosed |
| EP-2739623-B1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMA (US) | 2017-01-11 | — | — | EP | disclosed |
| US-20160355512-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2016-12-08 | — | — | US | disclosed |
| US-20160355512-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2016-12-08 | — | — | US | disclosed |
| WO-2016191079-A1 | IMPROVED PROCESS FOR PREPARING BORYL 7-AZAINDOLE COMPOUNDS | BOROPHARM, INC. (US) | 2016-12-01 | — | — | WO | disclosed |
| US-20160251353-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2016-09-01 | — | — | US | disclosed |
| US-20160251353-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2016-09-01 | — | — | US | disclosed |
| WO-2015073491-A1 | FORMULATIONS OF AZAINDOLE COMPOUNDS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015073481-A1 | METHODS OF PREPARING INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2015073476-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-05-21 | — | — | WO | disclosed |
| WO-2013019828-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008072-A1 | FORMULATIONS OF AZAINDOLE COMPOUNDS | H1-0, H1-5, H1-2 | GSK3A 1966/4885GSK3B 2194/4885LPL 2387/4885 |
| US-20160251353-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | CLIC1, NHERF1, ZC3HAV1 | GSK3A 3657/4885GSK3B 3607/4885LPL 3749/4885 |
| US-10023569-B2 | Methods of preparing inhibitors of influenza viruses replication | ZC3HAV1, ZC3HAV1L, POLR2H | GSK3A 560/4885GSK3B 517/4885LPL 4046/4885 |
| US-10640501-B2 | Methods of preparing inhibitors of influenza viruses replication | ZC3HAV1, ZC3HAV1L, POLR2H | GSK3A 560/4885GSK3B 517/4885LPL 4046/4885 |
| US-20180134730-A1 | IMPROVED PROCESS FOR PREPARING BORYL 7-AZAINDOLE COMPOUNDS | AZI2, BCCIP, ADAR | GSK3A 2267/4885GSK3B 2228/4885LPL 3046/4885 |
| US-11345700-B2 | Methods of preparing inhibitors of influenza viruses replication | ZC3HAV1, ZC3HAV1L, POLR2H | GSK3A 560/4885GSK3B 517/4885LPL 4046/4885 |
| US-20160355512-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, RNASEH1, ACE2 | GSK3A 997/4885GSK3B 924/4885LPL 1973/4885 |
| US-20200207765-A1 | METHODS OF PREPARING INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ZC3HAV1, ZC3HAV1L, POLR2H | GSK3A 560/4885GSK3B 517/4885LPL 4046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.